锌在癌症治疗中的细胞毒性/肿瘤抑制作用：一个谜和一个机会。
Cytotoxic/tumor suppressor role of zinc for the treatment of cancer: an enigma and an opportunity.
机构信息
Department of Oncology and Diagnostic Sciences, Dental School, University of Maryland, Baltimore, MA 21201, USA.
出版信息
Expert Rev Anticancer Ther. 2012 Jan;12(1):121-8. doi: 10.1586/era.11.190.
Abstract
A major issue relating to many cancers is the absence of effective chemotherapeutic agents; so that most often untreatable morbidity and death are prevalent once the cancer has been detected and has advanced. The search for efficacious anticancer agents is imperative. One potential agent is zinc, which is decreased in the development of some cancers in order to avoid its cytotoxic/tumor suppressor effects on the malignant cells. This provides the basis and opportunity to employ a treatment regimen that restores elevated zinc levels in the malignant cells and elicits the cytotoxic/tumor suppressor effects of zinc. The enigma is that this approach and expectation has not reached fruition. The question is "why?". This article provides a discussion of relevant zinc issues that need to be considered and resolved. Important areas of research are identified as being essential for the successful application of zinc cytotoxicity/tumor suppression actions for the treatment of specific cancers.
摘要
一个与许多癌症相关的主要问题是缺乏有效的化疗药物；因此，一旦癌症被发现并已经进展，往往就会出现无法治疗的发病率和死亡率。寻找有效的抗癌药物是当务之急。一种潜在的药物是锌，在某些癌症的发展过程中，锌的含量会降低，以避免其对恶性细胞的细胞毒性/肿瘤抑制作用。这为采用一种治疗方案提供了基础和机会，即在恶性细胞中恢复升高的锌水平，并引发锌的细胞毒性/肿瘤抑制作用。问题是，这种方法和期望并没有实现。问题是“为什么？”。本文讨论了需要考虑和解决的相关锌问题。确定了重要的研究领域，对于成功应用锌的细胞毒性/肿瘤抑制作用来治疗特定癌症是必不可少的。
相似文献
1
Cytotoxic/tumor suppressor role of zinc for the treatment of cancer: an enigma and an opportunity.
Expert Rev Anticancer Ther. 2012 Jan;12(1):121-8. doi: 10.1586/era.11.190.
2
Zinc as an anti-tumor agent in prostate cancer and in other cancers.
Arch Biochem Biophys. 2007 Jul 15;463(2):211-7. doi: 10.1016/j.abb.2007.02.033. Epub 2007 Mar 16.
3
The immunological contribution of NF-κB within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent.
Biochim Biophys Acta. 2012 Apr;1825(2):160-72. doi: 10.1016/j.bbcan.2011.11.002. Epub 2011 Nov 29.
4
Zn(II)-curcumin solid dispersion impairs hepatocellular carcinoma growth and enhances chemotherapy by modulating gut microbiota-mediated zinc homeostasis.
Pharmacol Res. 2019 Dec;150:104454. doi: 10.1016/j.phrs.2019.104454. Epub 2019 Sep 14.
5
Zinc overload mediated by zinc oxide nanoparticles as innovative anti-tumor agent.
J Trace Elem Med Biol. 2019 Jan;51:226-234. doi: 10.1016/j.jtemb.2018.08.002. Epub 2018 Aug 7.
6
AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Expert Opin Investig Drugs. 2012 Jun;21(6):891-9. doi: 10.1517/13543784.2012.685128.
7
Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve.
Prostate Cancer Prostatic Dis. 2004;7(2):111-7. doi: 10.1038/sj.pcan.4500712.
8
The status of zinc in the development of hepatocellular cancer: an important, but neglected, clinically established relationship.
Cancer Biol Ther. 2014 Apr;15(4):353-60. doi: 10.4161/cbt.27633. Epub 2014 Jan 21.
9
The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots.
Mol Cancer. 2006 May 15;5:17. doi: 10.1186/1476-4598-5-17.
10
Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.
Cell Cycle. 2011 May 15;10(10):1679-89. doi: 10.4161/cc.10.10.15642.
引用本文的文献
1
The Influence of Rolling Reduction on the Mechanical, Corrosion, Osteogenic, and Antibacterial Properties of Zn-Mg Alloys.
ACS Omega. 2025 Aug 16;10(33):37141-37153. doi: 10.1021/acsomega.5c01732. eCollection 2025 Aug 26.
2
The Correlation Between Zinc Intake and Superoxide Dismutase Activity with Cognitive Function in the Elderly.
Sultan Qaboos Univ Med J. 2025 May 2;25(1):506-514. doi: 10.18295/2075-0528.2866. eCollection 2025.
3
Metal Ion Signaling in Biomedicine.
Chem Rev. 2025 Jan 22;125(2):660-744. doi: 10.1021/acs.chemrev.4c00577. Epub 2025 Jan 2.
4
Synthesis of Zinc Oxide-Doped Carbon Dots for Treatment of Triple-Negative Breast Cancer.
Int J Nanomedicine. 2024 Dec 27;19:13949-13971. doi: 10.2147/IJN.S494262. eCollection 2024.
5
Zinc ions activate AKT and promote prostate cancer cell proliferation via disrupting AKT intramolecular interaction.
Oncogene. 2025 Jan;44(1):8-18. doi: 10.1038/s41388-024-03195-x. Epub 2024 Oct 23.
6
A metal-organic nanoframework for efficient colorectal cancer immunotherapy by the cGAS-STING pathway activation and immune checkpoint blockade.
J Nanobiotechnology. 2024 Sep 30;22(1):592. doi: 10.1186/s12951-024-02836-3.
7
Ultrasonic synthesis, characterization, DFT and molecular docking of a biocompatible Zn-based MOF as a potential antimicrobial, anti-inflammatory and antitumor agent.
Sci Rep. 2024 Sep 23;14(1):21989. doi: 10.1038/s41598-024-71609-7.
8
Investigating the Anticancer Potential of Zinc and Magnesium Alloys: From Base Materials to Nanocoated Titanium Implants.
Materials (Basel). 2024 Jul 8;17(13):3365. doi: 10.3390/ma17133365.
9
Nanoenabled intracellular zinc bursting for efficacious reversal of gefitinib resistance in lung cancer.
Int J Biol Sci. 2024 May 19;20(8):3028-3045. doi: 10.7150/ijbs.95929. eCollection 2024.
10
The p53 protein is a suppressor of Atox1 copper chaperon in tumor cells under genotoxic effects.
PLoS One. 2023 Dec 21;18(12):e0295944. doi: 10.1371/journal.pone.0295944. eCollection 2023.
本文引用的文献
1
The genetic/metabolic transformation concept of carcinogenesis.
Cancer Metastasis Rev. 2012 Jun;31(1-2):123-30. doi: 10.1007/s10555-011-9334-8.
2
Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma.
Cancer Biol Ther. 2011 Aug 15;12(4):297-303. doi: 10.4161/cbt.12.4.16356.
3
Evidence for operation of the direct zinc ligand exchange mechanism for trafficking, transport, and reactivity of zinc in mammalian cells.
J Inorg Biochem. 2011 May;105(5):589-99. doi: 10.1016/j.jinorgbio.2011.02.002. Epub 2011 Mar 29.
4
ZIP14 zinc transporter downregulation and zinc depletion in the development and progression of hepatocellular cancer.
J Gastrointest Cancer. 2012 Jun;43(2):249-57. doi: 10.1007/s12029-011-9269-x.
5
ZnT2-overexpression represses the cytotoxic effects of zinc hyper-accumulation in malignant metallothionein-null T47D breast tumor cells.
Cancer Lett. 2011 May 1;304(1):41-51. doi: 10.1016/j.canlet.2011.01.027. Epub 2011 Feb 25.
6
Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders.
CNS Neurosci Ther. 2012 Jan;18(1):41-6. doi: 10.1111/j.1755-5949.2010.00231.x. Epub 2010 Dec 27.
7
The role of survivin and Bcl-2 in zinc-induced apoptosis in prostate cancer cells.
Urol Oncol. 2012 Sep;30(5):562-8. doi: 10.1016/j.urolonc.2010.06.001. Epub 2010 Sep 6.
8
Differential zinc accumulation and expression of human zinc transporter 1 (hZIP1) in prostate glands.
Methods. 2010 Dec;52(4):316-21. doi: 10.1016/j.ymeth.2010.08.004. Epub 2010 Aug 10.
9
Survivin mediates prostate cell protection by HIF-1alpha against zinc toxicity.
Prostate. 2010 Aug;70(11):1179-88. doi: 10.1002/pros.21152.
10
Increased level of exogenous zinc induces cytotoxicity and up-regulates the expression of the ZnT-1 zinc transporter gene in pancreatic cancer cells.
J Nutr Biochem. 2011 Jan;22(1):79-88. doi: 10.1016/j.jnutbio.2009.12.001. Epub 2010 Apr 13.
Zotero 插件